MedTrace Logo

Chemotherapy Plus EGFR Monoclonal Antibody in Patients With Liver Metastases From Colorectal Cancer With ctDNA Superselective Negative Genes

NCT06490913 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2024-07-08

No results posted yet for this study

Summary

The purpose of this Phase II single-arm study is to prospectively explore the efficacy of chemotherapy plus EGFR inhibitors in patients with liver metastases from total wild-type colorectal cancer with ctDNA superselective negative genes.

Conditions

  • Liver Metastases of Colorectal Cancer

Interventions

DRUG

Capecitabine

1000mg/m2, bid, d1-d14，q3w，1cycle

DRUG

oxaliplatin

130mg/m2, ivgtt, d1，q3w，1cycle

DRUG

Cetuximab

cetuximab 500mg/m2, q2w

DRUG

Oxaliplatin

85mg/m2, d1,q2w

DRUG

Leucovorin

400mg/m2, d1,q2w

DRUG

5-FU

400mg/m2，d1,q2w

Sponsors & Collaborators

  • Fujian Cancer Hospital

    lead OTHER_GOV

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-01
Primary Completion
2025-06-30
Completion
2025-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06490913 on ClinicalTrials.gov